Drugs / Mixed bacteria
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05576961 | Sep 2022 → Dec 2024 | cancer | Sun Yat-sen University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mixed bacteria | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05576961 ↗ |
| Modality | Other / unclassified | “Cohort 3 uses a mixed bacteria including RX-af01, Bifidobacterium longum RX02 and Ligilactobacillus salivarius RX02” NCT05576961 ↗ |